

# **Molecular Diagnostics**

## **Part I: Technologies & Applications**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPMM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2021**

**A Jain PharmaBiotech Report**

## A U T H O R ' S   B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

## A B O U T   T H I S   R E P O R T

Prof. Jain wrote the first commercial report on DNA Diagnostics in 1995, which was published by PJB Publication, London. This was updated in 1997 as Molecular Diagnostics I and the next edition, Molecular Diagnostics II, was published in 1999 – both by Decision Resources Inc, USA. All the three versions of the reports were well accepted and sold widely. The current version was originally published by Jain PharmaBiotech in 2001 and is constantly updated and revised since then. Not only was this the first such report on molecular diagnostics, it is also the longest continuously published report on this topic (>25 years). It is also the most comprehensive and detailed report on this topic containing profiles of the largest number of companies involved in molecular diagnostics.

**November 2021 (continuously published since 1995)**  
**Copyright © 2021 by**

**Jain PharmaBiotech**  
Bläsiring 7  
CH-4057 Basel  
Switzerland

**Tel & Fax:** +4161-6924461  
**Email:** info@pharmabiotech.ch  
**Web site:** http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be left, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# T A B L E   O F   C O N T E N T S

<b>0. Executive Summary .....</b>	<b>25</b>
<b>1. Introduction .....</b>	<b>27</b>
<b>Definitions and scope of the subject .....</b>	<b>27</b>
<b>Historical evolution of molecular diagnostics.....</b>	<b>27</b>
<b>Molecular biology relevant to molecular diagnostics.....</b>	<b>28</b>
DNA .....	28
<i>DNA polymerases.....</i>	28
<i>Restriction endonucleases.....</i>	29
RNA .....	29
<i>RNA polymerases.....</i>	29
<i>Non-coding RNAs.....</i>	30
DNA transcription.....	30
Chromosomes .....	30
<i>Chromatin.....</i>	31
<i>Extrachromosomal DNA.....</i>	31
Telomeres.....	32
Mitochondrial DNA .....	32
Genes.....	33
<i>The genetic code.....</i>	33
<i>Gene expression.....</i>	33
The human genome .....	34
<i>ENCODE .....</i>	34
Variations in the human genome.....	35
<i>Variations in DNA sequences .....</i>	35
<i>Single nucleotide polymorphisms .....</i>	35
Haplotyping.....	36
<i>Copy number variations in the human genome .....</i>	36
<i>Genotype and haplotypes.....</i>	37
<i>Genomic imprinting .....</i>	38
<i>Insertions and deletions in the human genome .....</i>	38
<i>Complex chromosomal rearrangements .....</i>	39
<i>Large scale variation in human genome .....</i>	39
<i>Structural variations in the human genome .....</i>	39
<i>Replication of the DNA helix .....</i>	40
<i>Transposons.....</i>	40
Epigenetics/epigenomics.....	40
<i>DNA methylation.....</i>	41
Proteins .....	41
Proteomics .....	42
Monoclonal antibodies .....	42
Aptamers.....	42
<b>Basics of molecular diagnostics .....</b>	<b>43</b>
Tracking DNA: the Southern blot .....	43
Pulsed-field gel electrophoresis.....	43
DNA Probes.....	44
The polymerase chain reaction .....	44
<i>Basic Principles of PCR.....</i>	44
<i>Target selection .....</i>	45
<i>Detection of amplified DNA .....</i>	45
<b>Impact of human genome project on molecular diagnostics .....</b>	<b>45</b>
<i>Mapping and sequencing of structural variation from human genomes .....</i>	46
1000 Genomes Project .....	47
<i>Human Variome Project .....</i>	47
<b>Role of bioinformatics in molecular diagnostics .....</b>	<b>48</b>
<b>Systems biology approach to molecular diagnostics .....</b>	<b>48</b>
<b>Synthetic biology and molecular diagnostics .....</b>	<b>49</b>
<b>Biomarkers .....</b>	<b>49</b>
<b>Applications of molecular diagnostics.....</b>	<b>50</b>
<b>2. Molecular Diagnostic Technologies .....</b>	<b>53</b>
<b>Introduction .....</b>	<b>53</b>
<b>DNA sample collection and extraction.....</b>	<b>53</b>
Blood samples .....	53
Buccal swabs and saliva.....	53
Dried blood spots.....	54

Formalin-fixed, paraffin-embedded tissues .....	54
Manual vs automated DNA extraction .....	55
Urine samples for transrenal DNA .....	55
<b>Sample preparation .....</b>	<b>56</b>
Pressure Cycling Technology .....	56
<b>Membrane immobilization of nucleic acids.....</b>	<b>56</b>
<b>Automation of sample preparation in molecular diagnostics.....</b>	<b>57</b>
ABI PRISM 6700 Automated Nucleic Acid Workstation .....	57
BioRobot technology.....	57
COBAS AmpliPrep System .....	57
GENESIS FE500 Workcell .....	57
GeneMole.....	58
PCR BioCube .....	58
QIAsymphony.....	58
Tigris instrument system .....	58
Techniques for sample preparation suitable for automation .....	59
<i>Xtra Amp Genomic DNA Extraction.....</i>	59
<i>Extraction of DNA from paraffin sections .....</i>	59
<i>Dynabead technology .....</i>	59
<i>SamPrep.....</i>	59
Use of magnetic particles for automation in genome analysis .....	60
Companies involved in nucleic acid isolation .....	60
<b>Labeling and detection of nucleic acids.....</b>	<b>61</b>
<b>Novel PCR methods.....</b>	<b>62</b>
Addressing limitations of PCR .....	62
ARMS-PCR .....	62
CAST-PCR .....	63
Combined PCR-ELISA .....	63
Convection PCR .....	63
Co-Dx PCR .....	64
Digital PCR .....	64
Dumbbell PCR .....	65
Emulsion PCR .....	65
ExCyto PCR .....	66
Fast PCR .....	66
Immuno PCR .....	67
Long and accurate PCR .....	67
Multiplex PCR .....	67
Overlap extension PCR .....	67
Real-time PCR systems .....	68
<i>Dyes used in real-time PCR .....</i>	68
<i>Target-specific fluorogenic probes for monitoring real-time PCR.....</i>	69
<i>Applications of real-time PCR.....</i>	69
<i>Limitations of real-time PCR .....</i>	70
<i>Quantitative PCR for accurate low level DNA analysis.....</i>	70
<i>qPCR for quantification of mtDNA.....</i>	70
<i>Real-time qPCR for measuring the length of telomeres .....</i>	71
<i>Guidelines for real-time qPCR .....</i>	71
<i>Future applications of real-time qPCR .....</i>	71
Commercially available real-time PCR systems .....	72
<i>Life Technologies' Real-Time PCR systems.....</i>	73
<i>LightCycler PCR system .....</i>	73
<i>LightUp probes based on real-time PCR .....</i>	73
<i>PlexPCR based on PlexZyme technology.....</i>	74
<i>READ™ real-time PCR method .....</i>	75
<i>StellArray™ technology .....</i>	75
Reverse hybridization PCR assays .....	75
Reverse transcriptase (RT)-PCR .....	75
<i>Standardized reverse transcriptase PCR .....</i>	76
Single cell PCR .....	77
<i>LATE-PCR.....</i>	77
<i>COLD-PCR.....</i>	77
<i>AmpliGrid-System.....</i>	78
Solar thermal PCR system monitored by Smartphone .....	78
Ultrafast photonic PCR .....	79
<b>DNA melt analysis.....</b>	<b>79</b>
High-resolution DNA melt analysis for genotyping .....	79
PCR device for DNA melt analysis in space .....	79
<b>Monitoring of gene amplification in molecular diagnostics .....</b>	<b>80</b>
<b>Non-PCR nucleic acid amplification methods .....</b>	<b>80</b>

DNA probes with conjugated minor groove binder .....	80
DNAble .....	81
Dynamic Flux Amplification .....	81
Isothermal nucleic acid amplifications.....	81
<i>Isothermal reaction for amplification of oligonucleotides .....</i>	<i>81</i>
<i>Isothermal and chimeric primer-initiated amplification of nucleic acids.....</i>	<i>82</i>
<i>Loop-mediated amplification.....</i>	<i>82</i>
<i>Single Primer Isothermal Amplification .....</i>	<i>82</i>
<i>Strand Invasion Based Amplification.....</i>	<i>83</i>
Linked Linear Amplification.....	83
Multiplex Ligation-Dependent Probe Amplification .....	83
Rapid analysis of gene expression .....	83
Recombinase polymerase amplification .....	84
Rolling circle amplification technology.....	84
<i>Gene-based diagnostics through RCAT.....</i>	<i>85</i>
<i>RCAT-immunodiagnostics.....</i>	<i>86</i>
<i>RCAT-pharmacogenomics .....</i>	<i>86</i>
<i>Circle-to-circle amplification .....</i>	<i>86</i>
Ramification amplification method.....	86
Transcription mediated amplification .....	87
WAVE nucleic acid fragment analysis system .....	87
<b>Technologies for signal amplification.....</b>	<b>88</b>
3 DNA dendrimer signal amplification .....	88
Hybridization signal amplification method .....	89
Signal mediated amplification of RNA technology .....	90
Invader assays .....	90
Hybrid Capture technology .....	92
Branched DNA test.....	93
Tyramide signal amplification .....	93
Non-enzymatic signal amplification technologies .....	93
<b>Non-PCR methods for molecular diagnosis .....</b>	<b>94</b>
Direct molecular analysis without amplification .....	94
<i>Trilogy™ Platform .....</i>	<i>94</i>
<i>Direct detection of dsDNA .....</i>	<i>95</i>
<b>Multiplex assays .....</b>	<b>96</b>
<b>Fluorescent in situ hybridization.....</b>	<b>96</b>
FISH technique .....	97
Applications of FISH .....	98
Modifications of FISH.....	99
Direct visual in situ hybridization .....	99
Direct labeled Satellite FISH probes.....	99
Comparative genomic hybridization .....	99
Primed in situ labeling .....	100
Interphase FISH .....	100
FISH with telomere-specific probes .....	100
Multicolor FISH .....	101
<i>Simultaneous Ultrasensitive Subpopulation staining/Hybridization In situ .....</i>	<i>101</i>
Automation of FISH.....	101
Companies involved in FISH diagnostics.....	101
<b>RNA diagnostics.....</b>	<b>102</b>
RNA isolation from tissue samples.....	102
Commercially available tests for mRNA detection and quantitation .....	103
Branched-chain DNA assay for measurement of RNA.....	104
Cycling probe technology .....	104
Invader RNA assays .....	104
Linear RNA amplification .....	105
Non-isotopic RNase cleavage assay .....	105
Nucleic acid sequence-based amplification .....	105
Q Beta replicase system .....	107
RNAScope .....	108
RNA expression profiling .....	108
<i>Visualization of mRNA expression in vivo .....</i>	<i>108</i>
Solid Phase Transcription Chain Reaction .....	108
Transcriptome analysis .....	109
MicroRNA diagnostics .....	109
<i>Microarray vs quantitative PCR for measuring miRNAs .....</i>	<i>109</i>
<i>Microarrays for analysis of miRNA gene expression .....</i>	<i>110</i>
<i>miR-TRAP to identify miRNA targets in vivo.....</i>	<i>111</i>
<i>Modification of in situ hybridization for detection of miRNAs .....</i>	<i>111</i>
<i>Nuclease Protection Assay to measure miRNA expression.....</i>	<i>111</i>

<i>Real-time PCR for expression profiling of miRNAs</i> .....	<b>111</b>
<i>Use of LNA to explore miRNA</i> .....	<b>112</b>
<b>Whole genome amplification</b> .....	<b>112</b>
Companies that provide technologies for whole genome amplification.....	113
<i>QIAGEN's Repli-G system</i> .....	113
<i>GenomePlex™ Whole Genome Amplification</i> .....	113
<b>DNA sequencing</b> .....	<b>114</b>
Applications of next generation sequencing in molecular diagnostics .....	115
Companies developing sequencing for molecular diagnostics .....	116
Molecular diagnostics and sequencing in space .....	117
<b>Genome-wide approach for chromatin mapping</b> .....	<b>118</b>
<b>Mitochondrial sequencing</b> .....	<b>119</b>
Identification of unknown DNA sequences .....	119
<i>Mitochondrial exome sequencing</i> .....	120
<b>Optical mapping</b> .....	<b>120</b>
<b>Gene expression analysis</b> .....	<b>120</b>
Gene expression profiling on whole blood samples .....	121
Gene expression patterns of white blood cells.....	121
Gene expression profiling based on alternative RNA splicing .....	122
MAUI (MicroArray User Interface) hybridization .....	122
Monitoring in vivo gene expression by molecular imaging .....	123
Serial analysis of gene expression (SAGE).....	123
Single-cell gene expression analysis .....	123
T cell receptor expression analysis .....	124
Tangerine™ expression profiling .....	125
Whole genome expression array .....	125
Ziplex™ system .....	126
Companies involved in gene expression analysis.....	126
<b>Peptide nucleic acid technology</b> .....	<b>127</b>
Use of PNA with fluorescence in situ hybridization .....	127
PNA and PCR .....	128
Use of PNA with biosensors .....	129
PNA-based PD-loop technology .....	129
PNA-DNA hybrid quadruplexes.....	129
Companies involved in PNA diagnostics.....	130
<b>Locked nucleic acids</b> .....	<b>130</b>
<b>Zip Nucleic Acids</b> .....	<b>131</b>
<b>Electrochemical detection of DNA</b> .....	<b>131</b>
Mediated nucleic acid oxidation.....	131
Detection of hybridized nucleic acid with cyclic voltammetry .....	132
Electrochemical detection based on Toshiba's CMOS technology.....	132
Electrochemical detection of DNA for POC .....	133
Concluding remarks on electrochemical DNA detection .....	133
<b>Bead-based assay platforms</b> .....	<b>133</b>
Amplification Refractory Mutation System .....	134
<b>Nucleic acid lateral flow molecular diagnostics</b> .....	<b>135</b>
<b>Omics-based tests</b> .....	<b>136</b>
<b>3. Biochips, Biosensors, and Nanobiotechnology</b> .....	<b>137</b>
<b>Introduction to biochip technology</b> .....	<b>137</b>
<b>Applications of biochips in diagnostics</b> .....	<b>137</b>
GeneChip.....	138
<i>GeneChip Human Genome Arrays</i> .....	139
<i>AmpliChip CYP450</i> .....	139
Electronic detection of nucleic acids on microarrays.....	139
Microchip capillary electrophoresis .....	140
Strand displacement amplification on a biochip .....	140
Rolling circle amplification on microarrays.....	140
<i>LiquiChip-RCAT</i> .....	140
Fast PCR biochip .....	141
Multiplex microarray-enhanced PCR for DNA analysis .....	141
Multiplexed Molecular Profiling .....	141
Universal DNA microarray combining PCR and ligase detection reaction .....	142
Genomewide association scans .....	142
Whole genome chips/microarrays.....	143
Transposon insertion site profiling chip .....	143
Standardizing the microarrays .....	144
Companies involved in developing biochip technology for diagnostics .....	144
Future of biochip technology for molecular diagnostics.....	145
<b>Microfluidic chips</b> .....	<b>145</b>

Fish-on-chip .....	146
Lab-on-a-chip.....	146
LabCD .....	146
Micronics' microfluidic technology.....	147
Microfluidic chips/arrays using PCR .....	147
<i>Microfluidic automated DNA analysis using PCR .....</i>	<i>147</i>
<i>Digital PCR Array .....</i>	<i>147</i>
<i>Digital PCR on a SlipChip .....</i>	<i>147</i>
Microfluidic chips integrated with RCAT.....	148
Microfluidic chips integrated with PET .....	148
Companies developing microfluidic technologies .....	148
<b>Biosensor technologies .....</b>	<b>149</b>
Classification of biosensor technologies.....	150
DNA-based biosensors.....	151
<i>DNA hybridization biosensor chips.....</i>	<i>151</i>
<i>PCR-free DNA biosensors .....</i>	<i>151</i>
<i>DNA based biosensor to detects metallic ions .....</i>	<i>152</i>
Genetically engineered B lymphocytes.....	152
Biosensors immunoassays.....	152
PNA (peptide nucleic acid)-based biosensors .....	152
Protein-based biosensors .....	153
Antibody biosensors .....	153
Cell-based biosensors (cytosensors).....	153
<i>Multicell biosensors .....</i>	<i>154</i>
<i>Microbial biosensors .....</i>	<i>154</i>
Optical biosensors.....	154
<i>Surface plasmon resonance technology.....</i>	<i>155</i>
<i>Label-free optical biosensor.....</i>	<i>155</i>
Electrochemical sensors.....	156
<i>Enzyme electrodes for biosensing .....</i>	<i>156</i>
<i>Conductometric sensors.....</i>	<i>156</i>
<i>Electrochemical genosensors .....</i>	<i>156</i>
<i>Electrochemical nanobiosensor .....</i>	<i>157</i>
<i>Electrochemical microRNA biosensor .....</i>	<i>158</i>
Phototransistor biochip biosensor.....	158
Ribozyme-based sensors.....	158
<i>RiboReporters.....</i>	<i>159</i>
<i>Wearable biosensors .....</i>	<i>159</i>
Concluding remarks and future of biosensor technology .....	160
Companies developing biosensors for molecular diagnostics .....	160
<b>Molecular labels and detection .....</b>	<b>161</b>
Detection technologies for molecular labels .....	162
Fluorescence and chemiluminescence .....	162
<i>Fluorescence technologies for label detection.....</i>	<i>163</i>
<i>Companies with fluorescence and chemiluminescence products .....</i>	<i>163</i>
Molecular beacons.....	164
The Green fluorescent protein .....	165
Multiophoton detection radioimmunoassay .....	166
Multi-pixel photon counter .....	166
Enzyme labels and detection by fluorescence .....	166
Phase-sensitive flow cytometry .....	167
Microtransponder-based DNA diagnostics .....	167
Laboratory Multiple Analyte Profile .....	168
Multiple labels .....	168
<b>Protein-DNA chimeras for detection of small numbers of molecules.....</b>	<b>169</b>
<b>Single molecule detection .....</b>	<b>169</b>
Atomic force microscopy .....	170
Capillary electrophoresis .....	170
Confocal laser scanning .....	170
Time domain optical imaging technology.....	170
nCounter Analysis System.....	171
Spectrally resolved fluorescence lifetime imaging microscopy .....	171
<b>Molecular imaging .....</b>	<b>171</b>
Technologies for molecular imaging .....	171
<i>Positron emission tomography .....</i>	<i>172</i>
<i>Magnetic resonance imaging .....</i>	<i>172</i>
<i>Optoacoustic imaging .....</i>	<i>172</i>
<i>Computer tomography.....</i>	<i>173</i>
<i>Hyperpolarized diazirines for in vivo biomolecular imaging .....</i>	<i>173</i>
Basic research in molecular imaging .....	173

Devices for molecular imaging .....	173
Molecular imaging in clinical practice .....	174
Companies involved in molecular imaging .....	174
<b>Nanobiotechnology for molecular diagnostics.....</b>	<b>175</b>
Cantilever arrays .....	176
Diagnostics based on nanopore technology .....	177
DNA nanomachines for molecular diagnostics .....	177
Exosome-based molecular diagnostics .....	177
Fullerene photodetectors for chemiluminescence detection on microfluidic chip.....	178
Gold nanoparticles .....	178
Immunoliposome-PCR .....	178
Magnetic nanoparticles .....	179
Nanotechnology on a chip .....	179
NanoChip® Electronic Microarray.....	180
Nanobarcodes technology for molecular diagnostics .....	180
Nanosensors .....	181
<i>Detection of cocaine molecules by nanoparticle-labeled aptasensors.</i> .....	181
<i>Nanosensors for glucose monitoring .</i> .....	181
<i>PEBBLE nanosensors .</i> .....	182
<i>Quartz nanobalance biosensor .</i> .....	182
DNA nanoswitch-linked immunosorbent assay .....	182
Quantum dot technology.....	183
<i>Qdot nanobarcodes for multiplexed gene expression profiling.</i> .....	184
Resonance Light Scattering technology .....	184
Role of nanobiotechnology in improving molecular diagnostics.....	185
Companies involved in nanomolecular diagnostics .....	185
Concluding remarks about nanodiagnosis .....	188
Future of nanodiagnosis .....	188
<b>4. Proteomic Technologies for Molecular Diagnostics .....</b>	<b>191</b>
<b>Introduction .....</b>	<b>191</b>
<b>Proteomic technologies .....</b>	<b>191</b>
Biomarkers of disease .....	191
<i>Proteomic tools for biomarkers .</i> .....	191
<i>Search for biomarkers in body fluids.</i> .....	192
Captamers with proximity extension assay for proteins.....	192
Cyclical amplification of proteins .....	192
Detection of misfolded proteins by ELISA with exponential signal amplification .....	193
Detection of proteins by Western blot.....	193
Diagnostics based on designed repeat proteins .....	193
Differential Peptide Display .....	194
Light-switching excimer probes.....	194
MALDI-TOF MS .....	195
Molecular beacon aptamer .....	195
Molecular beacon assay .....	196
Proteomic patterns.....	196
Real-time PCR for protein quantification.....	197
<b>Protein biochip technologies.....</b>	<b>197</b>
ProteinChip .....	198
LabChip for protein analysis .....	199
TRINECTIN proteome chip.....	199
Protein chips for antigen-antibody interactions molecular diagnostics .....	199
Microfluidic devices for proteomics-based diagnostics .....	200
Nanotechnology-based protein biochips/microarrays .....	200
<i>Nanoparticle protein chip .</i> .....	200
<i>Protein nanobiochip.</i> .....	200
New developments in protein chips/microarrays .....	201
<i>Antibody microarrays .....</i> .....	201
<i>Aptamer-based protein biochip .</i> .....	201
<i>Multiplexed Protein Profiling on Microarrays.</i> .....	202
<i>Proteomic pattern analysis .....</i> .....	202
<i>Single molecule array .....</i> .....	202
<i>Viral protein chip .....</i> .....	202
Commercial development of protein chips for molecular diagnostics .....	203
Proteome Identification Kit .....	204
<b>Laser capture microdissection (LCM).....</b>	<b>204</b>
LCM technology .....	204
Applications of LCM in molecular diagnostics .....	205
<b>Proteomic diagnosis of CNS disorders.....</b>	<b>205</b>
Cerebrospinal fluids tests based on proteomics .....	205

Urine tests for CNS disorders based on proteins in urine .....	206
Diagnosis of CNS disorders by examination of proteins in the blood.....	206
Diagnosis of CNS disorders by examination of proteins in tears.....	207
Role of proteomics in the diagnosis of Alzheimer's disease .....	207
Role of proteomics in the diagnosis of Creutzfeldt-Jakob disease.....	208
Future of use of proteomics for diagnosis of CNS disorders.....	208
<b>Concluding remarks on the use of proteomics in diagnostics.....</b>	<b>208</b>
<b>5. Molecular Diagnosis of Genetic Disorders .....</b>	<b>211</b>
<b>Introduction .....</b>	<b>211</b>
<b>Cytogenetics .....</b>	<b>212</b>
FISH with probes to the telomeres .....	212
Single copy FISH probes .....	212
Comparative genomic hybridization .....	213
<b>Use of biochips in genetic disorders.....</b>	<b>213</b>
Representational oligonucleotide microarray analysis.....	214
<b>Diagnosis of genomic rearrangements by multiplex PCR .....</b>	<b>214</b>
<b>Quantitative fluorescent PCR .....</b>	<b>214</b>
<b>Mutation detection technologies.....</b>	<b>215</b>
PCR-based methods for mutation detection .....	216
<i>Cleavage Fragment Length Polymorphism</i> .....	216
<i>Direct dideoxy DNA sequencing</i> .....	216
<i>Digital Genetic Analysis (DGA)</i> .....	216
<i>Fluorescence-based directed termination PCR</i> .....	217
<i>Fluorescence melting curve analysis for multiplex mutation detection</i> .....	217
<i>Heteroduplex analysis</i> .....	217
<i>Restriction fragment length polymorphism</i> .....	218
<i>Single-stranded conformation polymorphism (SSCP) analysis</i> .....	218
<i>TaqMan real-time PCR</i> .....	219
Non-PCR methods for mutation detection.....	219
<i>Arrayed primer extension</i> .....	219
<i>BEAMing (beads, emulsion, amplification, and magnetics)</i> .....	220
<i>ELISA-protein truncation test</i> .....	220
<i>Enzymatic mutation detection</i> .....	220
<i>Specific anchor nucleotide incorporation</i> .....	220
<i>Conversion analysis for mutation detection</i> .....	221
Biochip technologies for mutation detection.....	221
<i>Combination of FISH and gene chips</i> .....	221
<i>Haplotype Specific Extraction</i> .....	222
Use of biosensors for detection of mutations .....	222
<b>Technologies for SNP analysis .....</b>	<b>222</b>
Acoustic detection of DNA conformation in genetic assays combined with PCR .....	224
DNA sequencing .....	224
Electrochemical DNA probes .....	224
<i>Use of NanoChip for detection of SNPs</i> .....	225
Laboratory Multiple Analyte Profile .....	225
Pathway enrichment and network analysis of GWAS.....	225
PCR-CTPP (confronting two-pair primers).....	226
PCR using one primer amplification of PCR-CTPP products.....	226
Peptide nucleic acid probes for SNP detection .....	226
Pyrosequencing .....	226
Reversed enzyme activity DNA interrogation test .....	227
Single base extension-tag array.....	228
Smart amplification process version 2 .....	228
SNP genotyping on a genome-wide amplified DOP-PCR template .....	228
SNP genotyping with gold nanoparticle probes.....	228
UCAN method (Takara Biomedical).....	229
Zinc finger proteins .....	229
<b>Biochip and microarray-based detection of SNPs.....</b>	<b>229</b>
SNP genotyping by MassARRAY .....	229
Electronic dot blot assay .....	230
Biochip combining BeadArray and ZipCode technologies .....	230
SNP-IT primer-extension technology .....	230
SNAPshot® Multiplex System for SNP genotyping .....	231
Affymetrix SNP genotyping array .....	231
Concluding remarks on SNP genotyping .....	231
Limitations of SNP in genetic testing.....	232
Haplotyping versus SNP genotyping .....	232
Nanofluidics technology for high throughput SNP genotyping.....	232
Companies involved in developing technologies/products for SNP analysis .....	233

<b>Role of copy number variations in genetic diagnostic testing .....</b>	<b>234</b>
CNVs in various diseases .....	234
<i>CNVs in genetic epilepsy syndromes.....</i>	234
<i>CNVs associated with schizophrenia .....</i>	235
Methods for determination of CNVs .....	235
<i>Digital array for CNV detection .....</i>	235
<i>Wellcome Trust Case Control Consortium CNV typing array.....</i>	236
<i>CNVer algorithm for CNV detection.....</i>	236
<i>CNVnator for discovery of CNVs and genotyping .....</i>	236
Study of rare variants in pinpointing disease-causing genes .....	237
<b>Chromothripsis and congenital abnormalities .....</b>	<b>237</b>
<b>Role of reanalysis of genomic sequence data in genetic diagnosis.....</b>	<b>238</b>
<b>Role of whole genome sequencing in screening of newborns .....</b>	<b>238</b>
<b>Prenatal DNA diagnosis .....</b>	<b>238</b>
Invasive prenatal diagnostic procedures .....	239
<i>Amniocentesis .....</i>	239
<i>Chorionic villus sampling.....</i>	239
Molecular methods for prenatal diagnosis.....	239
<i>aCGH for prenatal diagnosis .....</i>	239
<i>BAC HD Scan test .....</i>	239
<i>FISH for prenatal diagnosis .....</i>	240
<i>PCR for prenatal diagnosis .....</i>	240
<i>In vivo gene expression analysis of the living human fetus.....</i>	240
Non-invasive prenatal molecular diagnostic procedures .....	240
<i>Fetal cells separation from maternal blood for genetic diagnosis .....</i>	241
<i>Digital relative mutation dosage in maternal plasma.....</i>	241
<i>Prenatal testing based on transrenal DNA from urine .....</i>	241
<i>Reflex DNA screening protocol .....</i>	242
<i>Tests for preterm birth .....</i>	242
Tests on fetal DNA in maternal blood.....	242
<i>Sequencing-based methods for prenatal diagnosis from maternal DNA .....</i>	243
<i>cfDNA testing vs routine screening in first trimester of pregnancy .....</i>	244
<i>Noninvasive WGS of the fetus.....</i>	245
<i>Directed DNA analysis of maternal blood.....</i>	246
Applications of prenatal diagnosis .....	246
<i>Antenatal screening for Down's syndrome .....</i>	247
<i>Diagnosis of congenital infections.....</i>	248
<i>Diagnosis of eclampsia .....</i>	248
<i>Identification of cancers in pregnant women during NIPT .....</i>	249
<b>Preimplantation genetic diagnosis.....</b>	<b>249</b>
Technologies for preimplantation genetic diagnosis .....	249
<i>PCR for preimplantation genetic diagnosis.....</i>	249
<i>FISH for preimplantation genetic diagnosis.....</i>	250
<i>Microarrays for preimplantation genetic diagnosis .....</i>	250
<i>Whole genome sequencing for PGD .....</i>	251
Conditions detected by preimplantation genetic diagnosis .....	251
The future of preimplantation genetic diagnosis .....	251
<b>Companies involved in prenatal/preimplantation diagnosis .....</b>	<b>252</b>
<b>Cystic fibrosis .....</b>	<b>253</b>
Detection of CFTR gene mutations .....	253
CFTR technologies of various companies .....	254
<i>Asuragen's bead array test.....</i>	255
<i>Ambry CF Test.....</i>	255
<i>Biochip for CF diagnosis.....</i>	256
<i>CF Plus™ Tag-It Cystic Fibrosis Kit .....</i>	256
<i>HerediT™ (SEQUENOM) CF carrier screening test .....</i>	256
<i>Identification of CF variants by PCR/Oligonucleotide Ligation Assay .....</i>	257
<i>LabCorp's CF gene sequencing.....</i>	257
<i>MiSeqDx sequencing-based CF assays .....</i>	257
<i>Serum proteomic signature for CF using antibody microarrays.....</i>	257
Guidelines for genetic screening for CF .....	257
<b>Congenital adrenal hyperplasia.....</b>	<b>258</b>
<b>Primary immunodeficiencies.....</b>	<b>258</b>
<b>Hematological disorders .....</b>	<b>259</b>
Hemoglobinopathies .....	259
<i>Sickle cell anemia .....</i>	260
<i>Thalassemia .....</i>	260
<i>Paroxysmal nocturnal hemoglobinuria.....</i>	261
Hemophilia .....	261
Hereditary hemochromatosis .....	261

<b>Polycystic kidney disease .....</b>	<b>262</b>
<b>Hereditary metabolic disorders.....</b>	<b>262</b>
Lesch-Nyhan Syndrome .....	262
Gaucher's Disease.....	262
Acute Intermittent Porphyria .....	263
Phenylketonuria.....	263
Hereditary periodic fever.....	263
<b>Achondroplasia .....</b>	<b>264</b>
<b>Molecular diagnosis of eye diseases .....</b>	<b>264</b>
Molecular diagnosis of retinitis pigmentosa.....	264
Genetic screening for glaucoma .....	265
<b>Role of molecular diagnostics in rheumatoid arthritis.....</b>	<b>265</b>
<b>Molecular diagnosis of neurogenetic disorders .....</b>	<b>265</b>
Alzheimer's disease.....	267
Autism spectrum disorders.....	267
<i>CNVs associated with autism</i> .....	268
Charcot-Marie Tooth disease .....	268
Down syndrome.....	269
Duchenne and Becker muscular dystrophy .....	269
eNOS gene polymorphisms as predictor of cerebral aneurysm rupture.....	270
Fragile X syndrome .....	271
Huntington disease .....	271
Hereditary neuropathy with liability to pressure palsies.....	272
Mitochondrial disorders affecting the nervous system .....	272
Parkinson's disease .....	272
Pompe's disease .....	273
Spinal muscular atrophy .....	273
Triple repeat disorders.....	274
<b>Genetic testing for disease predisposition .....</b>	<b>274</b>
Direct-to-consumer genetic tests .....	275
<b>Genetic diagnosis in patients with previously undiagnosed disease .....</b>	<b>277</b>
<b>6. Molecular diagnosis of cardiovascular disorders.....</b>	<b>279</b>
<b>Introduction .....</b>	<b>279</b>
<b>Coronary heart disease .....</b>	<b>280</b>
Genomics of coronary heart disease .....	280
Diagnosis of coronary artery disease based on gene expression.....	281
<b>Cardiomyopathy.....</b>	<b>281</b>
Hypertrophic cardiomyopathy .....	281
Idiopathic dilated cardiomyopathy .....	281
<b>Cardiac arrhythmias .....</b>	<b>282</b>
Genetic tests for cardiac arrhythmias .....	282
Long Q-T syndrome.....	282
Familial atrial fibrillation.....	283
Idiopathic ventricular fibrillation.....	283
<b>Congestive heart failure.....</b>	<b>283</b>
<b>Hypertension .....</b>	<b>283</b>
<b>Disturbances of blood lipids.....</b>	<b>284</b>
Familial dyslipoproteinemias.....	284
Hypercholesterolemia .....	284
<b>Thrombotic disorders.....</b>	<b>285</b>
Factor V Leiden mutation .....	285
Pulmonary embolism .....	285
Hereditary thrombophilia .....	286
<b>Molecular diagnostics for monitoring heart transplant rejection.....</b>	<b>286</b>
AlloMap® molecular expression testing.....	286
<b>Commercial molecular diagnostics for cardiovascular disorders .....</b>	<b>287</b>
<b>7. Molecular Diagnosis of Infections .....</b>	<b>289</b>
<b>Introduction .....</b>	<b>289</b>
<b>Molecular techniques for the diagnosis of infections .....</b>	<b>289</b>
Antibody-enhanced microplate hybridization assays .....	290
Bacteriophage-based methods for detection of bacteria .....	290
Biochips/microarrays for detection of microorganisms .....	291
<i>Lawrence Livermore Microbial Detection Array</i> .....	291
Biosensors for detection of microorganisms .....	291
<i>Ibis T5000™ Biosensor System</i> .....	291
<i>Molecular Mirroring Technology</i> .....	291
DNA enzyme immunoassay .....	292
DNA biochip/microarray in diagnosis of infections .....	292

DNA-based typing methods .....	293
<i>Restriction fragment length polymorphism analysis</i> .....	293
<i>Ribotyping</i> .....	293
<i>Random amplified polymorphic DNA</i> .....	293
<i>Combinatorial DNA melting assay</i> .....	293
Electrochemical detection of pathogens .....	294
Field Activated Sample Treatment (FAST) .....	294
FISH for detection of infections .....	294
<i>hemoFISH assay</i> .....	295
Helicase-dependent isothermal amplification for rapid detection of pathogens .....	295
High resolution melt analysis for diagnosis of infections .....	295
Immunomagnetic cell capture .....	295
Ligase chain reaction .....	296
MRI for diagnosis of infections .....	296
Multiplex PCR for detection of infections .....	297
Metagenomic pyrosequencing .....	297
<i>Dual priming oligonucleotide for multiplex PCR</i> .....	298
<i>Multiplex amplified nominal tandem repeat analysis</i> .....	299
Nanopore-based diagnosis of infections .....	299
NASBA for detection of microorganisms .....	299
Nucleic acid probes .....	299
Neutrophil CD11b expression as a diagnostic marker .....	300
Optical Mapping .....	300
PCR electrospray ionization mass spectrometry .....	300
PNA-FISH for diagnosis of infections .....	301
Proteomic technologies for diagnosis of infections .....	301
<i>Mass spectrometry for microbial identification</i> .....	301
QuantiFERON® technology for pre-molecular diagnosis of infections .....	302
Quantitative reverse-transcription PCR for bacterial diagnostics .....	303
Rapid electrochemical diagnosis of infections .....	303
Rupture event scanning .....	303
Real-time single-molecule imaging of virus particles .....	303
Single-strand conformational polymorphism .....	304
SmartGene platform for identifying pathogens based on genetic sequences .....	304
Tessera array technology .....	304
Tests for sepsis .....	304
<i>LightCycler® SeptiFast Test</i> .....	305
<i>NanoDx™</i> .....	305
<i>Next-generation sequencing assay to detect cell-free microbial DNA</i> .....	305
<i>SeptiCyte Triage assay</i> .....	306
<i>SepsiTTest™</i> .....	306
<i>VYOO® Sepsis Test</i> .....	306
Unyvero Solution .....	306
<b>Applications, advantages and limitations of molecular diagnostics.....</b>	<b>306</b>
Molecular diagnostics versus other microbial detection technologies .....	307
Advantages of nucleic acid-based diagnostics in infections .....	307
Drawbacks of nucleic acid-based diagnostics in infections .....	307
Nanotechnology for detection of infectious agents .....	308
<b>Bacterial infections .....</b>	<b>309</b>
Mycobacterium tuberculosis .....	312
Conventional diagnosis of tuberculosis .....	312
<i>Combined tuberculin skin testing and ELISpot<sup>PLUS</sup> assay</i> .....	313
<i>Microscopic Observation Drug Susceptible Assay for tuberculosis</i> .....	313
Molecular diagnostics for tuberculosis .....	313
<i>Diagnosis of TB in a POC setting</i> .....	315
<i>Diagnosis of drug-resistant MTB infection</i> .....	315
<i>Gene expression blood test for detecting TB</i> .....	316
<i>GenXpert MTB/RIF (eXpert) automated molecular test for MTB</i> .....	317
<i>QuantiFERON-TB Gold test</i> .....	317
<i>Transcriptional signatures in active vs asymptomatic tuberculosis</i> .....	317
Diagnosis of other mycobacteria .....	318
<i>Leprosy and M. leprae</i> .....	318
Bacteria associated with bacterial vaginosis .....	319
Chlamydial infections .....	319
<i>Neisseria gonorrhoeae</i> .....	320
<i>Trichomonas vaginalis</i> .....	321
Streptococcal infections .....	321
<i>Group B Streptococci</i> .....	321
<i>Group A Streptococcus and Streptococcus dysgalactiae</i> .....	322
<i>Pseudomonas aeruginosa</i> .....	322

<i>Helicobacter pylori</i> .....	322
<i>Vibrio Cholerae</i> .....	323
Lyme disease .....	323
Mycoplasmas.....	324
<b>Fungal infections .....</b>	<b>325</b>
PCR-based tests for fungal infections .....	325
DNA barcode marker for fungi .....	326
DNA sequencing for fungal infections.....	326
MALDI-TOF MS for diagnosis of fungal infections.....	326
Aspergillus .....	326
Candida species .....	327
<b>Viral infections.....</b>	<b>328</b>
Carbon nanotubes-based detection of viruses.....	328
Sensitive metagenomic sequencing for detection of pathogenic human viruses .....	328
Simultaneous testing of multiple viruses by VirScan.....	329
FDA-approved molecular diagnostics for viral infections .....	329
HIV/AIDS.....	330
<i>Diagnosis of HIV</i> .....	330
<i>Detection of HIV provirus</i> .....	331
<i>Global Surveillance of HIV-1 genetic variations</i> .....	331
<i>Genotyping for drug-resistance in HIV</i> .....	332
<i>Neonatal screening of infants of HIV-positive mothers</i> .....	333
<i>Phenotyping as predictor of drug susceptibility/resistance in HIV</i> .....	333
<i>POC testing for HIV</i> .....	334
<i>PCR for resolution of indeterminate Western blot</i> .....	334
<i>Screening of cadaveric tissue donors</i> .....	335
<i>Tests used for quantification of HIV</i> .....	335
<i>Conclusions about HIV diagnostics</i> .....	336
Hepatitis viruses .....	337
<i>Hepatitis A virus</i> .....	337
<i>Hepatitis B virus</i> .....	337
<i>Hepatitis C virus</i> .....	338
<i>Detection and quantification of HCV RNA</i> .....	338
<i>Quantification of HCV RNA levels as a guide to antiviral therapy</i> .....	339
<i>Electrochemical DNA chip for diagnosis of HCV</i> .....	339
<i>HCV Genotyping as a guide to therapy</i> .....	339
<i>Hepatitis E</i> .....	340
Enteroviruses .....	340
Adenoviruses.....	341
Rhinoviruses .....	341
Herpes viruses.....	342
<i>Herpes simplex virus</i> .....	342
<i>Genital and neonatal herpes simplex</i> .....	342
<i>Human cytomegalovirus infections</i> .....	343
<i>Epstein-Barr virus</i> .....	343
Human papilloma virus .....	344
<i>Molecular diagnostics for HPV</i> .....	344
Detection of encephalitis viruses .....	345
<i>West Nile and St. Louis encephalitis</i> .....	345
<i>Venezuelan equine encephalitis virus</i> .....	346
Detection of noroviruses .....	346
Detection of dengue virus .....	346
Detection of Ebola virus.....	347
Detection of Zika virus.....	347
<b>Protozoal infections .....</b>	<b>348</b>
Amebiasis .....	348
Cryptosporidium parvum.....	349
Leishmaniasis .....	349
Malaria .....	349
Neurocysticercosis .....	350
Pneumocystis carinii.....	350
Toxoplasmosis .....	350
<b>Infections of various systems.....</b>	<b>351</b>
CNS infections .....	351
<i>Molecular diagnosis in bacterial meningitis</i> .....	351
<i>Molecular diagnosis in herpes simplex encephalitis</i> .....	352
<i>Diagnosis of transmissible spongiform encephalopathies</i> .....	352
Molecular diagnosis of respiratory viruses .....	353
<i>Avian influenza H7N9</i> .....	354
<i>H1N1 influenza</i> .....	354

<i>Influenza viruses</i> .....	357
<i>Avian influenza H5N1</i> .....	359
<i>Coronaviruses</i> .....	361
<i>Coronavirus China 2019</i> .....	363
<i>Nucleic acid-based testing for SARS-CoV-2</i> .....	363
<i>Detection of variants of SARS-CoV-2</i> .....	364
<i>COVID-19 diagnostics</i> .....	364
<i>BioFire Respiratory Panel 2.1 (RP2.1)</i> .....	381
<i>Serological assay for detection of SARS-CoV-2 antibodies</i> .....	381
<i>POC diagnostics for COVID-19</i> .....	382
<i>Tests for SARS-CoV-2 variants</i> .....	383
<i>FDA's role in molecular diagnostic testing for COVID-19</i> .....	383
<i>Reassessment of molecular diagnostics for COVID-19</i> .....	384
<i>Gastrointestinal infections</i> .....	384
<i>Periodontal infections</i> .....	385
<i>Diagnosis of urinary infections by a biosensor</i> .....	386
<i>Role of molecular diagnosis in sexually transmitted infections</i> .....	387
<i>Role of molecular diagnostics in septicemia</i> .....	387
<b>Limitations and needs of diagnostics for infections</b> .....	<b>387</b>
Cell-based methods for identifying pathogenic microorganisms.....	388
<i>Cell-based virus assays</i> .....	388
<i>Cell-based detection of host response to infection</i> .....	388
<b>Role of molecular diagnostics in hospital acquired infections</b> .....	<b>389</b>
Molecular diagnostics for detection of drug resistance in infections.....	389
Detection of hospital-acquired bacterial infections .....	389
<i>Detection of methicillin-resistant <i>S. aureus</i></i> .....	389
<i>Whole-genome sequencing for investigation of MRSA outbreaks</i> .....	391
<i>Detection of carbapenemase-producing Gram-negative bacteria</i> .....	391
<i>Detection of vancomycin-resistant enterococci</i> .....	392
<i>Detection of hospital-acquired <i>C. difficile</i></i> .....	392
<i>Integrated device for rapid detection of organisms associated HAI</i> .....	394
<i>Bacterial genome sequencing in antimicrobial resistance</i> .....	394
<i>Detection of hospital-acquired viral infections</i> .....	394
<i>Molecular diagnosis of BK virus</i> .....	395
<i>Diagnosis of hospital-acquired rotavirus gastroenteritis</i> .....	395
<b>Molecular diagnostics and the microbiome</b> .....	<b>395</b>
Human Microbiome Project.....	396
Application of metagenomics for study of the microbiome .....	396
MicroBiome Analysis Center .....	397
<b>Concluding remarks and future of diagnosis of infections</b> .....	<b>397</b>
Rapid point-of-care diagnosis of infections .....	398
Diagnosis of viruses using protein fingerprinting .....	400
QIAplex PCR multiplex technology .....	401
Role of PCR vs sequencing for diagnosis of infections.....	401
<b>Companies involved in molecular diagnosis of infectious diseases</b> .....	<b>402</b>
<b>8. Molecular Diagnosis of Cancer</b> .....	<b>405</b>
<b>Introduction</b> .....	<b>405</b>
<b>Cancer genomics</b> .....	<b>405</b>
Cancer genes .....	406
Oncogenes .....	406
Tumor Suppressor Genes .....	406
<i>BRCA mutations</i> .....	407
<i>p53</i> .....	408
<i>p16</i> .....	408
CNVs in cancer .....	408
<i>Allele-specific copy number analysis of tumors</i> .....	409
Viruses and cancer .....	409
<i>Detecting viral agents in cancer</i> .....	410
<b>Conventional cancer diagnosis</b> .....	<b>411</b>
<b>Molecular techniques for cancer diagnosis</b> .....	<b>412</b>
Exosome-based molecular diagnosis of cancer .....	413
Expression profiling of tumor cells sorted by flow cytometry .....	414
MicroRNA expression profiling for cancer diagnostics .....	414
Genome analysis at the molecular level .....	414
Mutation detection by sequencing .....	415
Quality control of NGS in oncology .....	415
Biomarkers in cancer .....	415
<i>Circulating nucleic acids as potential biomarkers of cancer</i> .....	416
<i>Circulating nucleosomes in serum of cancer patients</i> .....	416

<i>Detection of DNA methylation</i>	417
<i>eTag assay system for cancer biomarkers</i>	419
<i>HAAH as a biomarker for cancer</i>	419
<i>LigAmp for detection of gene mutations in cancer</i>	419
<i>Methylscape biomarker of cancer</i>	420
<i>Mitochondrial DNA as a cancer biomarker</i>	420
<i>NIPT for detecting biomarkers of gynecological cancers</i>	420
<i>Oncoproteins as biomarkers for cancer</i>	421
<i>Sequencing-based approaches for detection of cancer biomarkers</i>	421
<i>Molecular fingerprinting of cancer</i>	422
<i>Fluorescent in situ hybridization</i>	422
<i>Genetic analysis of cancer</i>	423
<i>Comparative genomic hybridization in cancer diagnostics</i>	423
<i>Loss of heterozygosity</i>	423
<i>Digital karyotyping</i>	423
<i>Gene expression profiles predict chromosomal instability in tumors</i>	424
<i>PCR Techniques</i>	424
<i>Cold-PCR</i>	425
<i>Real-time qPCR for diagnosis of cancer</i>	425
<i>Real-time PCR with myT™ Primer reagents</i>	425
<i>Antibody-based diagnosis of cancer</i>	426
<i>Monoclonal antibodies for diagnosis of cancer</i>	426
<i>Recombinant antibodies as a novel approach to cancer diagnosis</i>	426
<i>Combined immunological and nucleic acid tests</i>	426
<i>Combination of MAbs and RT-PCR</i>	426
<i>Immunobead RT-PCR</i>	427
<i>Assays for determining susceptibility to cancer</i>	427
<i>Gene expression profiling in cancer</i>	427
<i>Microarrays for gene expression profiling in cancer</i>	428
<i>Serial analysis of gene expression (SAGE)</i>	428
<i>Suppression subtractive hybridization</i>	428
<i>Cancer tests based on gene expression profiling</i>	429
<i>Measurement of telomerase activity</i>	429
<i>Liquid biopsy for detection of circulating tumor cells and cfDNA in body fluids</i>	430
<i>ApoStream for POC detection of CTCs</i>	431
<i>BEAMing technology for quantification of circulating tumor DNA</i>	431
<i>CEE (cell enrichment and extraction) technology</i>	431
<i>CellSearch</i>	431
<i>CellTracks® AutoPrep® System</i>	431
<i>CTCscope system for detection of CTCs</i>	432
<i>CTChip™</i>	432
<i>CTC sorting by acoustic waves</i>	432
<i>Detection of circulating tumor DNA</i>	433
<i>Droplet digital PCR for examination of cell free plasma DNA in cancer</i>	433
<i>DNA nanospheres for isolation of CTCs</i>	434
<i>Fiber-optic array scanning technology</i>	434
<i>Herringbone-chip for detection of CTCs</i>	434
<i>IsoFlux System</i>	434
<i>Lab-on-chip for the isolation and detection of CTCs</i>	435
<i>MagSweeper</i>	435
<i>Nano-Velcro to capture CTCs for diagnosis of cancer</i>	435
<i>NanoFlares for detection of CTCs</i>	436
<i>Companies developing tests for detection of CTCs</i>	436
<i>Future of detection of cancer cells in blood</i>	437
<i>Epithelial aggregate separation and isolation</i>	437
<i>Proteomic technologies for the molecular diagnosis of cancer</i>	437
<i>Proteomic technologies for tumor biomarkers</i>	437
<i>Affibodies as contrast agents for imaging in cancer</i>	438
<i>Aptamer-based technology for protein signatures of cancer cells</i>	438
<i>Aptamer probes for in vivo diagnosis of cancer</i>	439
<i>Aptamers for combined diagnosis and therapeutics of cancer</i>	439
<i>Automated image analysis of nuclear protein distribution</i>	439
<i>Laser capture microdissection in oncology</i>	440
<i>Layered expression scanning</i>	440
<i>Membrane-type serine protease-1</i>	441
<i>Survivin and molecular diagnosis of cancer</i>	441
<i>Biochip/microarrays for cancer diagnosis</i>	441
<i>Role of DNA microarrays in gene expression profiling</i>	442
<i>Biochip detection of FHIT gene</i>	442
<i>Multiplexed single-cell analysis of FFPE cancer tissue samples</i>	443

Nanobiotechnology for early detection of cancer .....	443
<i>Detection of nanoparticle self assembly in tumors by MRI</i> .....	443
<i>Differentiation between normal and cancer cells by nanosensors</i> .....	443
<i>Magnetic nanoparticle probes</i> .....	444
<i>Quantum dots for early detection of cancer</i> .....	444
Molecular imaging of cancer .....	445
<i>In vivo imaging of single cancer cells</i> .....	445
<i>In vivo molecular imaging of cancer</i> .....	445
<i>In vivo tumor illumination by adenoviral-GFP</i> .....	446
<i>PET for in vivo molecular diagnosis of cancer</i> .....	447
<i>Radiolabeled peptide-based targeting probes for cancer imaging</i> .....	447
<i>Xenon-enhanced MRI</i> .....	447
Detection of micrometastases.....	448
Detection of cancer stem cells .....	448
Detection of origin in cancers of unknown primary .....	448
<b>Molecular diagnosis of cancers of various organs .....</b>	<b>449</b>
Brain tumors .....	449
<i>Molecular diagnostic methods for brain tumors</i> .....	449
<i>Glioblastoma</i> .....	450
<i>Circulating microvesicles as biomarkers of glioblastoma</i> .....	450
<i>Circulating tumor cells in glioblastoma</i> .....	450
<i>Combination of neuroimaging and microarray analysis in glioblastoma</i> .....	451
<i>Medulloblastoma</i> .....	451
<i>Multigene predictor of outcome in glioblastoma</i> .....	451
<i>Oligodendrogloma</i> .....	452
<i>Advantages and limitations of molecular diagnosis of brain tumors</i> .....	452
Breast cancer .....	452
<i>Breast cancer genes</i> .....	453
<i>Circulating tumor cells and nucleic acid biomarkers of breast cancer</i> .....	454
<i>Genomic profiles of breast cancer</i> .....	454
<i>Imaging biopsy specimens as alternative to histological examination</i> .....	455
<i>Microchimerism and breast cancer</i> .....	455
<i>Molecular diagnostic tests for breast cancer</i> .....	455
<i>Molecular diagnostics for management of breast cancer</i> .....	459
<i>Mouse ESC-based assays to evaluate mutations in BRCA2</i> .....	463
<i>One step nucleic acid amplification assay for breast sentinel nodes</i> .....	464
<i>Prognostic testing for of breast cancer</i> .....	464
<i>Prediction of recurrence in breast cancer for personalizing therapy</i> .....	466
Cervical cancer .....	467
Colorectal cancer .....	469
<i>ColoVantage CRC test</i> .....	469
<i>Detection of familial adenomatous polyposis coli</i> .....	469
<i>Detection of CRC at precancerous state</i> .....	469
<i>Detection of circulating tumor cells in CRC</i> .....	470
<i>Diagnosis of hereditary nonpolyposis CRC</i> .....	470
<i>Diagnosis of CRC from DNA in stools</i> .....	471
<i>Droplet Digital™ PCR for detection of KRAS Mutations</i> .....	471
<i>Early diagnosis of CRC from blood samples</i> .....	471
<i>Guanyllyl cyclase C-based tests for CRC</i> .....	472
<i>Multitarget stool DNA testing for CRC screening</i> .....	472
Gastric cancer .....	473
Head and neck cancer .....	473
<i>Nanobiochip sensor technique for analysis of oral cancer biomarkers</i> .....	473
<i>ProteinChip for diagnosis of head and neck cancer</i> .....	473
Hematological malignancies .....	474
<i>Chromosome translocations</i> .....	474
<i>Flow cytometry in diagnosis of leukemia</i> .....	474
<i>Gene chip technology</i> .....	474
<i>Hairy-cell leukemia</i> .....	475
<i>Laboratory assessment of leukemia</i> .....	475
<i>Molecular probes</i> .....	476
<i>Minimal residual disease</i> .....	476
<i>Molecular diagnosis in myelodysplastic syndromes</i> .....	477
<i>Screening of gene mutations in chronic myeloproliferative diseases.</i> .....	477
Lung cancer .....	478
<i>Biomarkers of immune response in lung cancer</i> .....	478
<i>Early diagnosis of lung cancer</i> .....	478
<i>Gene abnormalities in lung cancer</i> .....	479
<i>Liquid biopsy based on CTCs in lung cancer</i> .....	479
<i>Methylation profiling of lung cancer</i> .....	480

<i>Molecular subtyping of lung cancer.....</i>	480
<i>Prediction of efficacy of chemotherapy.....</i>	480
Melanoma.....	481
Ovarian cancer .....	481
<i>Mutation of genes .....</i>	481
<i>Relevance of genetic testing to management of ovarian cancer.....</i>	482
<i>Serum biomarkers for early detection of ovarian cancer.....</i>	482
<i>Biomarkers of ovarian cancer .....</i>	482
<i>Concluding remarks on testing for ovarian cancer .....</i>	483
Pancreatic cancer.....	483
<i>Proteomic techniques for diagnosis of pancreatic cancer .....</i>	483
<i>Detection of KRAS mutations in pancreatic cancer.....</i>	484
Prostate cancer.....	484
<i>Identification of genetic risks for prostate cancer .....</i>	484
<i>Gene expression analysis of prostate cancer.....</i>	484
<i>Huntingtin Interacting Protein 1 .....</i>	485
<i>Integrative genomic and proteomic profiling of prostate cancer .....</i>	485
<i>LCM for diagnosis of prostate cancer .....</i>	485
<i>Liquid biopsy for prostate cancer patients .....</i>	486
<i>Mitomic™ prostate test.....</i>	486
<i>Nanotechnology for early detection of recurrence of prostate cancer .....</i>	487
<i>PCA3 gene detection in urine.....</i>	487
<i>PCR assay for assessing silencing of protein cadherin 13 gene .....</i>	488
<i>Polaris test.....</i>	488
<i>Prostate biopsy for detection of prostatic intraepithelial neoplasia .....</i>	488
<i>Prostate Core Mitomic Test™ .....</i>	488
<i>Prostat Health Index .....</i>	489
<i>Screening of multiple SNPs for risk of prostate cancer .....</i>	489
<i>Semen testing for prostate cancer biomarkers .....</i>	489
<i>Serum-protein fingerprinting in prostate cancer .....</i>	490
<i>Tissue-based epigenetic test for prostate cancer .....</i>	490
Thyroid cancer.....	490
<i>Afirma gene expression classifier for inconclusive thyroid biopsies.....</i>	490
<i>Gene expression biomarkers of thyroid cancer.....</i>	491
<i>Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer.....</i>	491
<i>miRNA expression profiling in thyroid cancer .....</i>	491
Urinary bladder cancer .....	492
<b>Role of molecular diagnostics in the management of cancer .....</b>	<b>492</b>
Risk assessment and prevention of cancer .....	492
Role of molecular diagnosis in the design of future cancer therapies.....	493
Molecular classification of cancer.....	493
Determination of cancer prognosis .....	494
<i>Prognosis by tumor classification .....</i>	494
<i>Prognosis by cancer gene expression .....</i>	494
Selection of anticancer drugs based on molecular diagnosis .....	494
Integrated genome-wide analysis of cancer for diagnosis and therapy .....	495
<b>Role of molecular diagnostics in personalized therapy for cancer.....</b>	<b>495</b>
Personalized diagnosis of cancer .....	495
Pharmacogenetics and cancer therapy .....	496
Molecular diagnostics as an aid to selection of cancer therapy .....	497
Drug resistance in cancer.....	497
<b>Role of organizations in molecular diagnosis of cancer.....</b>	<b>497</b>
Role of NCI in molecular diagnosis of cancer.....	497
<i>Molecular profiling of cancer .....</i>	498
<i>Cancer Genome Atlas .....</i>	498
<i>Support for future research in molecular diagnosis of cancer .....</i>	498
Role of the International Cancer Genome Consortium.....	498
<b>Future of molecular diagnosis of cancer .....</b>	<b>499</b>
<b>Companies involved in molecular diagnosis of cancer.....</b>	<b>499</b>

## **9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare ... 503**

<b>Introduction .....</b>	<b>503</b>
<b>Molecular diagnostics in biopharmaceutical industry.....</b>	<b>503</b>
Molecular diagnostic technologies and drug discovery .....	504
Molecular diagnostics and pharmacogenetics .....	504
Molecular toxicology .....	505
<i>Gene expression studies for toxicology .....</i>	506
<i>Toxicogenomics .....</i>	506
<i>Toxicoproteomics .....</i>	507
Mitochondrial assays .....	508

MetaChip/Datachip.....	508
Molecular diagnostics and pharmacogenomics .....	509
Molecular diagnostics and therapeutic drug monitoring .....	510
Applications molecular diagnostics in gene therapy .....	510
<i>Use of PCR to study biodistribution of gene therapy vectors .....</i>	510
<i>PCR for verification of the transcription of DNA .....</i>	511
<i>In situ PCR for direct quantification of gene transfer into cells.....</i>	511
<i>Detection of retroviruses by reverse transcriptase (RT)-PCR.....</i>	511
<i>Assessment of safety issues of gene transfer.....</i>	511
<i>Quantitative PCR for monitoring the effectiveness of gene therapy .....</i>	512
<i>Use of FISH for analysis of adeno-associated viral vector integration .....</i>	512
<i>Monitoring of gene expression by green fluorescent protein.....</i>	512
Quality control of protein therapeutics and vaccines .....	512
Detection of microbial contamination in biopharmaceutical manufacturing.....	513
<i>Role of PCR in detecting contamination .....</i>	513
<i>Systems for rapid detection of contaminants .....</i>	513
<i>Contamination of biopharmaceuticals with prions .....</i>	514
DNA tagging for control and tracing of drug distribution channels .....	514
<b>Molecular diagnostics for organ transplantation.....</b>	<b>515</b>
<i>HLA typing .....</i>	515
<i>Sequencing for HLA typing .....</i>	516
<i>Commercial products for transplant molecular diagnostics.....</i>	516
<i>Post-cardiac transplant patient monitoring for rejection .....</i>	518
<b>Application of molecular diagnostics in blood transfusion .....</b>	<b>519</b>
<i>Molecular diagnostics for testing transfusion compatibility .....</i>	519
<i>Transmission of infections in blood transfusion .....</i>	520
<i>Molecular tests for screening of blood supply for viruses .....</i>	520
<i>Commercial molecular diagnostic technologies for blood screening .....</i>	521
<i>Bridge amplification technology .....</i>	521
<i>COBAS AmpliScreen HCV and HIV Assays .....</i>	522
<i>INACTINE .....</i>	522
<i>NucliSens Extractor system .....</i>	522
<i>Pall's enhanced Bacteria Detection System.....</i>	523
<i>PCR combined with algorithm method .....</i>	523
<i>Prions detection in human blood .....</i>	523
<i>PRISM® automated system .....</i>	524
<i>Procleix HIV-1/HCV Assay .....</i>	524
<i>West Nile virus detection in human blood.....</i>	525
<i>Zika virus screening of US blood donors.....</i>	525
<i>Advantages and limitations of molecular diagnostics for blood screening .....</i>	525
<b>Molecular epidemiology .....</b>	<b>526</b>
<i>Molecular epidemiology of genetic diseases .....</i>	527
<i>Role of CNVs in study of genetic epidemiology .....</i>	527
<i>Accumulation of CNVs with aging .....</i>	527
<i>Monogenic versus polygenic disorders .....</i>	528
<i>Critical issues facing genetic epidemiology .....</i>	528
<i>Molecular epidemiology of infectious diseases.....</i>	529
<i>Methods and purposes .....</i>	529
<i>Emerging infections.....</i>	529
<i>Human vs. non-human infections.....</i>	530
<i>Genetics and susceptibility to infectious disease .....</i>	530
<i>Molecular epidemiology of cancer.....</i>	530
<i>Molecular epidemiology of p53 gene mutations .....</i>	531
<i>Molecular epidemiology of link between virus and cancer .....</i>	531
<i>Molecular epidemiology and cancer prevention .....</i>	532
<i>SNPs and molecular epidemiology .....</i>	532
<b>Molecular diagnostics for identification of food-borne pathogens.....</b>	<b>532</b>
<i>Introduction .....</i>	532
<i>Molecular diagnostic methods used in food-borne infections .....</i>	533
<i>Limitations of use of molecular probes in food analysis .....</i>	533
<i>Detection of Listeria-contaminated foods .....</i>	534
<i>Optical biosensor for detection of Listeria .....</i>	534
<i>Real-time PCR for detection of Listeria .....</i>	534
<i>Sequencing for investigation of food-borne Listeria infections .....</i>	535
<i>Detection of Salmonella .....</i>	535
<i>MicroSEQ® Salmonella Detection Kit .....</i>	535
<i>E. Coli detection.....</i>	535
<i>MicroSEQ® E. Coli Detection Kit .....</i>	536
<i>DuPont Bax system .....</i>	536
<i>MLG method for detection of multiple STEC strains .....</i>	536

<i>Detection of rare strains of E. Coli</i> .....	536
Companies with technologies for food pathogen detection .....	537
Transmissible spongiform encephalopathies (TSEs) .....	539
<i>Basis of molecular diagnosis of prion diseases</i> .....	539
<i>Molecular diagnosis of TSEs</i> .....	540
<i>Companies involved in developing molecular diagnostics for TSEs</i> .....	543
<b>Detection of genetically modified food.....</b>	<b>544</b>
<b>Molecular diagnostics for detection of doping in sports .....</b>	<b>545</b>
Screening of synthetic glucocorticosteroids in human urine .....	545
Detection of gene doping .....	546
<b>Role of molecular diagnostics in future healthcare .....</b>	<b>546</b>
Translation of genomic research into genetic testing for healthcare .....	546
Molecular diagnostics and disease management.....	547
Role of genetic biomarkers in disease management.....	547
Role of molecular diagnostics in personalized medicine .....	547
Integrated healthcare.....	548
<i>Screening</i> .....	548
<i>Early diagnosis</i> .....	548
<i>Prevention</i> .....	549
<i>Therapy based on molecular diagnosis</i> .....	549
<i>Monitoring of therapy</i> .....	549
<i>Advantages and limitations of integrated healthcare</i> .....	549
<i>Commercially available systems for integrated healthcare</i> .....	550
Combination of diagnostics and therapeutics .....	550
<i>Companion diagnostics</i> .....	550
<i>Companies involved in companion diagnostics</i> .....	551
Point-of-care diagnosis .....	552
<i>Advantages versus disadvantages of POC diagnosis</i> .....	554
<i>Technologies for point-of-care diagnosis</i> .....	554
<i>Biochips for POC diagnosis</i> .....	556
<i>CRISPR for POC diagnosis</i> .....	557
<i>Mobile detection of infections by microfluidic LAMP and smartphone</i> .....	558
<i>Nanosensors for POC diagnosis</i> .....	558
<i>POC Diagnostic Initiative</i> .....	558
<i>Paper-based POC diagnostic for infectious diseases</i> .....	559
<i>Synthetic biomarker-based POC diagnostic for cancer</i> .....	559
<i>Future of POC testing</i> .....	560
<i>Companies developing POC diagnosis</i> .....	561
The impact of molecular diagnostics on clinical laboratory practice .....	563
<b>10. Molecular Diagnostics in Forensic Medicine and Biological Warfare ..</b>	<b>565</b>
<b>Application of molecular diagnostics in forensic medicine .....</b>	<b>565</b>
Technologies .....	565
<i>ABO genotyping</i> .....	565
<i>DNA analysis for identification of ancient or historical specimens</i> .....	566
<i>DNA fingerprinting and short tandem repeats</i> .....	566
<i>DNA processing of forensic samples</i> .....	567
<i>DNA profiles from fingerprints</i> .....	567
<i>Fluorescent detection systems</i> .....	568
<i>Genome wide association studies linking genes to facial features</i> .....	568
<i>Mitochondrial DNA analysis</i> .....	568
<i>Next generation sequencing for forensic diagnosis</i> .....	569
<i>Pressure cycling technology for forensic applications</i> .....	570
<i>Polymorphic Alu insertions</i> .....	570
<i>SNP analysis</i> .....	570
Applications .....	570
<i>Applications in criminology</i> .....	571
<i>Identification of remains of military personnel</i> .....	572
<i>Identification of remains of victims of mass disasters</i> .....	572
<i>Parentage testing</i> .....	574
<i>Gender determination</i> .....	575
Companies developing molecular diagnostics for forensic science .....	575
<b>Molecular detection of biological warfare agents.....</b>	<b>576</b>
Introduction to biological warfare agents .....	576
Role of PCR in the diagnosis of biological warfare agents.....	577
<i>Multiplex PCR microarray assay to detect bioterror pathogens in blood</i> .....	578
Laboratory diagnosis of Anthrax.....	578
Challenges in diagnosis of biological warfare agents .....	579
US government efforts for detection of biological warfare agents .....	579
<i>The US Army Medical Research Institute of Infectious Diseases</i> .....	580

<i>Homeland Security Advance Research Projects Agency .....</i>	580
<i>Handheld Isothermal Silver Standard Sensor.....</i>	581
<i>Hapten mediated display and pairing of rAbs for biothreat assays .....</i>	581
<i>Commercial development of diagnostic devices for biological agents.....</i>	582
<i>Companies developing diagnostic devices for biological agents .....</i>	582
<i>Various devices for testing .....</i>	584
<i>Airborne bacterial spore detection technology.....</i>	584
<i>Analyte 2000 biosensor .....</i>	584
<i>Bead ARray Counter .....</i>	585
<i>Benchtop living cell biosensor.....</i>	585
<i>BioThreat Alert Test Strip.....</i>	585
<i>BioForce NanoArray sensor technology .....</i>	586
<i>Biodefence microarray .....</i>	586
<i>Biosensor based on mass spectrometry of microorganisms's RNA.....</i>	587
<i>Destruction and detection of anthrax by lysin .....</i>	587
<i>Hand-Held Advanced Nucleic Acid Analyzer .....</i>	587
<i>Identification of genetic markers of individual pathogens .....</i>	587
<i>Microbial Identification System based on OptiChip™ .....</i>	588
<i>MicroChemLab.....</i>	588
<i>Nanode Array Sensor Microchips .....</i>	589
<i>ProteinChip-based detection of bioterrorism agents .....</i>	589
<i>QTL handheld biosensor.....</i>	589
<i>TIGER biosensor .....</i>	589
<i>The PathAlert™ Detection System .....</i>	590
<i>VereThreat™ .....</i>	590
<i>Concluding remarks about biodefense applications of diagnostics .....</i>	590
<b>11. References .....</b>	<b>593</b>

## Tables

Table 1-1: Landmarks in development of molecular technology and its application to diagnosis .....	27
Table 1-2: Applications of molecular diagnostics .....	50
Table 2-1: Companies with products for nucleic acid isolation.....	60
Table 2-2: Applications of real-time PCR.....	69
Table 2-3: Some commercially available real-time PCR systems .....	72
Table 2-4: A selection of companies with commercially available FISH diagnostics .....	102
Table 2-5: Selected companies with RNA diagnostic tests .....	103
Table 2-6: Companies involved in whole genome amplification .....	113
Table 2-7: Companies involved in application of sequencing in molecular diagnostics .....	116
Table 2-8: Comparison of methods of identification of unknown DNA sequences.....	119
Table 2-9: Classification of methods of gene expression analysis .....	121
Table 2-10: A selection of companies with gene expression technologies .....	126
Table 2-11: Companies involved in developing PNA diagnostics .....	130
Table 2-12: Companies with bead-based diagnostic assay platforms .....	134
Table 2-13: Companies developing nucleic acid lateral flow molecular diagnostics.....	136
Table 3-1: Applications of biochip technology in relation to molecular diagnostics .....	137
Table 3-2: Companies developing whole genome chips/microarrays.....	143
Table 3-3: Companies involved in biochips for molecular diagnostics.....	144
Table 3-4: Companies developing microfluidic technologies.....	149
Table 3-5: Biosensor technologies with potential applications in molecular diagnostics .....	150
Table 3-6: Important applications of biosensors .....	160
Table 3-7: Companies involved in application of biosensors in molecular diagnostics .....	161
Table 3-8: Selected labels for nucleic acid detection.....	161
Table 3-9: Selected companies with fluorescence and chemiluminescence products .....	163
Table 3-10: Companies involved in molecular beacon manufacture and research .....	165
Table 3-11: Selected companies involved in molecular imaging .....	174
Table 3-12: Nanotechnologies with potential applications in molecular diagnostics .....	175
Table 3-13: Companies developing nanomolecular diagnostics .....	185
Table 4-1: Applications of protein biochips/microarrays .....	197
Table 4-2: Companies involved in developing diagnostic applications of protein biochips.....	203
Table 4-3: Disease-specific proteins in the cerebrospinal fluid of patients.....	205
Table 5-1: Mutation detection technologies .....	215
Table 5-2: Technologies for SNP analysis .....	223
Table 5-3: A sampling of companies involved in technologies for SNP genotyping .....	233
Table 5-4: Application of preimplantation genetic diagnosis in monogenic disorders .....	251
Table 5-5: Companies involved in prenatal/preimplantation diagnostics.....	252
Table 5-6: CFTR genotyping in cystic fibrosis – companies and technologies.....	254

Table 5-7: X-linked immunodeficiency disorders .....	259
Table 5-8: Available molecular diagnostics for neurogenetic diseases .....	266
Table 5-9: Companies offering genetic screening tests directly to consumers .....	275
Table 6-1: Genes that cause cardiovascular diseases .....	279
Table 6-2: Molecular diagnostics for cardiovascular diseases: commercial development.....	287
Table 7-1: Molecular techniques for the diagnosis of infections .....	289
Table 7-2: Commercially available molecular diagnostics for <i>sepsis</i> .....	304
Table 7-3: FDA-approved molecular diagnostics for various bacterial infections .....	309
Table 7-4: Commercially available molecular diagnostics for fungal infections .....	325
Table 7-5: FDA-approved molecular diagnostics for viral infections .....	329
Table 7-6: Companies with molecular diagnostics for influenza virus H1N1 .....	355
Table 7-7: Companies with molecular diagnostics for avian influenza virus H5N1 .....	359
Table 7-8: Molecular SARS-CoV-2 Diagnostic Tests for COVID-19 .....	364
Table 7-9: Commercially available molecular diagnostics for <i>C. difficile</i> .....	394
Table 7-10: Companies developing POC tests for the diagnosis of infections.....	398
Table 7-11: Selected companies involved in molecular diagnosis of infections .....	402
Table 8-1: Estimated new cases of cancer in the US of most involved organs - 2020.....	405
Table 8-2: Tumor suppressor genes, their chromosomal location, function, and associated tumors ....	407
Table 8-3: Viruses linked to human cancer .....	410
Table 8-4: A classification of molecular diagnostic methods in cancer .....	412
Table 8-5: Desirable characteristics of biomarkers for cancer .....	416
Table 8-6: Approved monoclonal antibodies for cancer diagnosis .....	426
Table 8-7: Methods for comparison of gene-expression profiling in tumor specimens .....	427
Table 8-8: Companies that have important cancer tests based on gene signatures .....	429
Table 8-9: Companies developing technologies for detection of CTCs .....	436
Table 8-10: Impact of in vivo molecular imaging of cancer on oncology practice.....	446
Table 8-11: Molecular diagnostic tests for breast cancer .....	455
Table 8-12: Companies developing cancer molecular diagnostics .....	499
Table 9-1: Applications of molecular diagnostics in the biopharmaceutical industry .....	503
Table 9-2: Molecular diagnostic technologies for drug discovery .....	504
Table 9-3: Molecular diagnostic technologies used for pharmacogenetic studies.....	504
Table 9-4: Companies with novel molecular toxicology technologies .....	505
Table 9-5: Applications of molecular diagnostics in gene therapy .....	510
Table 9-6: Companies involved in transplant molecular diagnostics .....	516
Table 9-7: Companies involved in molecular diagnostics of blood transfusions.....	521
Table 9-8: Pathogenic bacteria in food and targets for molecular diagnostic probes.....	533
Table 9-9: Companies involved in molecular diagnostics for food-borne infections .....	538
Table 9-10: Testing for harmful prions in brain tissue from dead cattle.....	540
Table 9-11: Companies involved in developing molecular diagnostics for TSEs .....	543
Table 9-12: Companies involved in detection of genetically modified food .....	544
Table 9-13: Companies involved in companion diagnostics.....	551
Table 9-14: Applications of point-of-care diagnosis .....	553
Table 9-15: Companies developing point-of-care diagnostic tests .....	561
Table 10-1: Forensic and legal applications of molecular diagnostics.....	570
Table 10-2: Molecular technologies used for forensic applications .....	576
Table 10-3: Biological and chemical agents used as weapons of mass destruction.....	577
Table 10-4: Biological warfare agents that can be identified by PCR methods .....	577
Table 10-5: Companies developing devices for detection of biological warfare agents.....	582

## Figures

Figure 1-1: Extrachromosomal DNA .....	31
Figure 1-2: Relation of molecular diagnostics to other technologies.....	51
Figure 2-1: PlexZyme technology for PlexPCR .....	74
Figure 2-2: Rolling circle amplification technology.....	84
Figure 2-3: A schematic view of the Invader operating system .....	92
Figure 2-4: Principle of fluorescent in situ hybridization .....	97
Figure 2-5: Repli-G system of QIAGEN .....	113
Figure 2-6: DNA sequencing process .....	115
Figure 2-7: Electrochemical detection of DNA .....	132
Figure 2-8: Elements of a Scorpions primer .....	135
Figure 3-1: Affymetrix GeneChip technology .....	138
Figure 3-2: Basic principle of a biosensor.....	150
Figure 3-3: Surface plasmon resonance (SPR) technology.....	155
Figure 7-1: Use of DNA chips in diagnosing microbial infections .....	292
Figure 7-2: High throughput DNA pyrosequencing for pathogen discovery .....	298
Figure 9-1: The mechanism of SHERLOCK for POC diagnosis .....	557